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Introduction
Protection of pulmonary mucosal surfaces from infection requires 
complex interplay between the airway epithelial cells and mono-
nuclear phagocyte populations both resident within the lung (1). 
Airway macrophages function as required accessory cells for opti-
mal lung performance, with adverse consequences arising from 
either insufficient or excessive activation. Bronchial epithelial 
cells maintain an intact mucosal barrier, and transmit inhibitory 
signals to airway macrophages, maintaining homeostatic control 
of airway inflammation. In response to bacterial infection, neutro-
phil recruitment into the inflamed lung from the circulating neu-
trophil compartment is a necessary and closely regulated phenom-
enon, with avoidable tissue damage the consequence for excessive 
neutrophil infiltration. The determinants and controls maintain-
ing pulmonary immune homeostasis and regulating inflammatory 
responses remain poorly defined. Recently, we discovered that the 
circadian clock exerted a major impact on the airway inflammato-
ry response to challenge (2).
The central clock lies in the suprachiasmatic nucleus of the 
brain and maintains essential synchrony of peripheral tissue 
clocks via neural and humoral mediators. Virtually all cells in the 
body express components of the cellular circadian clock and are 
capable of sustaining circadian oscillations. This cellular circa-
dian oscillator consists of a positive arm — CLOCK and BMAL1 
heterodimers — driving transcription of 2 inhibitory arms — PER/
CRY and REV-ERBĮ/REV-ERBȕ (also known as NR1D1 and 
NR1D2), which feed back to inhibit BMAL1/CLOCK heterodimer 
transactivation function (3). The circadian clock powerfully regu-
lates inflammation (4–6). Multiple measures of innate immunity 
show strong time-of-day variation, including cell trafficking to 
tissues, and monocyte/macrophage responses to TLR activation 
(7, 8), but far less is known about circadian control of inflamma-
tion in an organ context, such as the lung. Previously, we identi-
fied a strong time-of-day variation in pulmonary inflammation, 
and response to pneumococcal infection, a prevalent infectious 
challenge to the lung (2). This study showed that circadian clock 
disruption by deletion of the essential clock gene BMAL1 in the 
myelomonocytic cells had little impact, but that BMAL1 deletion 
in the airway epithelial cells, driven by CCSP-iCre transgene, aug-
mented inflammation across the circadian cycle. The circadian 
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function, macrophage activation, and energy metabolism (5, 17). 
Lack of potency coupled with low in vivo efficacy has stalled fur-
ther development for REV-ERB ligands as therapeutics for human 
application; however, these molecules offer invaluable tools to dis-
sect REV-ERB function.
Here we explore the hypothesis that REV-ERBĮ within the air-
way epithelial cells, and the sentinel macrophages, plays a critical 
role in pulmonary inflammation, and that REV-ERBĮ serves as a 
signaling relay for 2-way communication between the core circadi-
an clock and elaboration of the inflammatory reaction. We identify 
distinct roles for REV-ERBĮ within bronchial epithelial cells and 
myelomonocytic cells in setting the amplitude and timing of neu-
trophilic inflammation in the lung. We find that REV-ERBĮ is dom-
inant over REV-ERBȕ, but that there is some redundancy between 
the 2 paralogs. We identify a pathway linking inflammatory cyto-
kine signaling through phosphorylation to SUMOylation, ubiquiti-
nation, and degradation of REV-ERBĮ protein, thereby relieving 
inhibition of the inflammatory response. We identify and test a 
new REV-ERB inverse agonist, which acts to inhibit inflammato-
ry signaling, in part by stabilizing REV-ERBĮ protein, rendering 
it resistant to SUMO and ubiquitin modification. Thus, the clock/
immune interface is susceptible to pharmacological intervention.
Results
REV-ERBĮ plays a critical role in regulation of lung inflammation. 
Previously, we have shown that BMAL1 deletion in the bronchi-
al epithelium blocks circadian transcriptional cycles specifically 
in these cells, impacts on oxidative stress responses, suppresses 
both REV-ERBĮ and ȕ expression, and both abolishes time-of-day 
variation and augments pulmonary neutrophilic inflammation (2). 
Conditional deletion of BMAL1 is widely used in experimental 
models, as this is the only core molecular element driving circa-
dian cycles in which suppression of function leads to abolition of 
rhythmic transcriptional oscillations in the cell. In order to iden-
tify specific circadian-regulated proteins that directly couple to 
the regulation of immunity, we focused on the circadian REV-ERB 
transcription factors, which have been previously been identified 
as strong candidates for the regulation of diverse physiological 
functions, including rhythmic regulation of hepatic metabolism 
and adipose tissue (14, 18). To identify the role of REV-ERBĮ in 
circadian control of lung inflammation, we first raised a mono-
clonal antibody that specifically detects REV-ERBĮ but not its 
paralog REV-ERBȕ (Supplemental Figure 1; supplemental mate-
rial available online with this article; https://doi.org/10.1172/
JCI93910DS1). This antibody revealed a marked daily pattern of 
REV-ERBĮ protein expression in whole lung, with a peak in the 
day around zeitgeber time ZT8–12 for WT mice, and absence of 
expression in knockout mice (Figure 1A). By convention, ZT0 is 
the time of lights-on. Protein expression was in close phase to the 
transcript rhythms, with peak expression between ZT8 and ZT12, 
suggesting a rapid transcriptional-translation process and turn-
over of the protein (Supplemental Figure 2A).
We tested responses of global REV-ERBĮ knockout (hereafter 
defined as Rev-ErbĮ–/–) and WT mice to nebulized lipopolysac-
charide (LPS) at ZT4, when REV-ERBĮ protein is accumulating, 
and harvested animals 5 hours later, at peak of REV-ERBĮ. We 
observed an exaggerated neutrophilic inflammation in knockout 
effect in epithelial cells was explained by aberrant regulation of a 
single dominant neutrophil chemokine, CXCL5.
BMAL1 plays many roles in addition to being a core circadian 
clock component. The immune regulatory functions of BMAL1 
have been proposed to lie with regulation of the downstream 
REV-ERB transcription factors (5), CLOCK regulation of NF-ĸB 
function (9), and microRNA regulation (10). BMAL1 is not tracta-
ble to drug therapy; therefore, identifying how BMAL1 regulates 
lung inflammation is important to realize benefits in the clinic. 
The orphan nuclear receptor REV-ERBĮ has been shown to be an 
important intermediary molecular link between the core clock 
and inflammatory pathways in macrophages (5), possibly medi-
ated by direct DNA binding to the promoters of proinflammatory 
chemokines (11), but also involving inhibition of distal proinflam-
matory cytokine enhancers selected by macrophage-lineage- 
determining factors (12).
New insights into REV-ERB biology have resulted from loss-
of-function studies, and application of chemical biology tools to 
manipulate function (5, 13–15). These include the discovery that 
REV-ERBĮ and ȕ are functionally redundant in terms of main-
taining circadian oscillations, with only a minor change in peri-
od length seen in REV-ERBĮ–null mice (13, 16). However, a fas-
cinating discovery was the functional dissociation between the 
DNA-binding domain (DBD) functions of REV-ERBĮ, required 
for circadian clock regulation, and the DBD-independent func-
tions, necessary for regulation of rhythmic hepatic lipid metabo-
lism. This serendipitous finding resulted from a failed loxP gene 
targeting approach, which deleted the DBD as an in-frame cas-
sette, resulting in expression of a hypomorph allele, REV-ERBĮ-
DBDm (14). This striking finding revealed that only a minority of 
the REV-ERBĮ target gene spectrum was affected by loss of the 
DBD, and that REV-ERB recruitment to DNA elements was driven 
in large part by the cell lineage–determining transcription factors 
HNF4A and HNF6 in the liver. REV-ERBĮ, as a nuclear receptor, is 
a tractable drug target, with synthetic ligands regulating core clock 
Figure 1. REV-ERBĮ plays a critical role in regulation of lung inflamma-
tion. (A) Whole-lung REV-ERBĮ protein across the day (ZT, time from 
lights on). REV-ERBĮ densitometry (mean ± SEM) was normalized to 
ȕ-actin and to WT at ZT0; n = 5 for WT and n = 3 for Rev-ErbĮ–/– per time 
point. (B) Mice were exposed to aerosolized LPS at ZT4 and culled 5 hours 
later; cellular infiltrates were quantified in BAL using flow cytometry. Data 
presented as mean ± SEM; n = 6–8, ***P < 0.001 (2-way ANOVA, post hoc 
Bonferroni). Veh, vehicle. (C) H&E staining and immunohistochemistry 
for the neutrophil maker (NIMP/R14) of lung sections from mice after 
LPS challenge at 2 mg/ml. Representative of n = 4; scale bars: 50 ȝm. (D) 
Cytokine/chemokine levels in BAL fluid from mice exposed to aerosolized 
LPS (2 mg/ml). Representative of n = 8, Student’s t test with Welch’s 
correction. (E) Quantitative PCR (qPCR) analysis of cytokine transcripts in 
alveolar macrophages isolated from mice and stimulated ex vivo with LPS 
at 100 ng/ml for 2 hours. Data normalized to WT and presented as mean ± 
SEM; n = 3, *P < 0.05, **P < 0.01, ***P < 0.001 (Student’s t test). FC, fold 
change. (F) Ten-day cigarette smoke exposures were performed between 
ZT8 and ZT10, and animals were culled 20 hours after the last exposure. 
Cellular infiltrates were quantified in BAL using a hemocytometer for total 
cell number and cytospin for neutrophil and macrophage counts. Data 
presented as mean ± SEM; n = 6–10, *P < 0.05, ***P < 0.001 (2-way ANO-
VA, post hoc Bonferroni). (G) Chemokine levels in BAL fluid after 10-day 
cigarette smoke exposures. Data presented as mean ± SEM; n = 6–10, **P 
< 0.01 (2-way ANOVA, post hoc Bonferroni).
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mental Table 2 and Supplemental Figure 2C), indicating a broad-
er spectrum of REV-ERBĮ activity.
To extend these observations, we isolated alveolar macro-
phages from Rev-ErbĮ–/– mice and showed that these exhibited 
increased ex vivo cytokine responses to LPS, including Il-6 (Figure 
1E). However, we did not observe significant changes in Cxcl1 and 
Cxcl2 chemokines, while for Cxcl5 the primary source in pulmo-
nary tissues is the epithelium and not alveolar macrophages (19).
We extended these observations to other innate inflammato-
ry stimuli and assessed responses to a single exposure of cigarette 
smoke, a prevalent real-world environmental challenge to the 
lung. No cellular inflammatory responses were detected follow-
ing this transient challenge, but Cxcl5 transcript was significantly 
elevated specifically in lungs of Rev-ErbĮ–/– mice (Supplemental 
Figure 2, D and E). Following multiple smoke exposures (10 days), 
there was mortality of 3 of the 9 Rev-ErbĮ–/– mice, but none of the 
mice (Figure 1, B and C), accompanied by significantly augment-
ed chemokine and inflammatory cytokine responses, including 
CXCL5, the chemokine required to mediate the BMAL1 effect (ref. 
2, Figure 1D, and Supplemental Table 1).
We have previously shown exaggerated pulmonary inflam-
matory responses at ZT0 compared with ZT12 (2). Therefore, 
we repeated the challenges at the anticipated peak and trough of 
this natural inflammatory response oscillation (ZT0 and ZT12). 
These studies again revealed an increase in neutrophilic inflam-
mation in WT mice at ZT0 versus ZT12, but Rev-ErbĮ–/– mice 
showed augmented responses at both time points, and loss of 
diurnal variation (Supplemental Figure 2, B and C, and Supple-
mental Table 2). The most striking genotype difference was seen 
at ZT12, and at that time point the knockout mouse bronchoalve-
olar lavage (BAL) chemokines CXCL1, CXCL2, and G-CSF were 
elevated, but we did not see any difference in CXCL5 (Supple-
Figure 2. REV-ERBĮ in myeloid and airway epithelium regulates pulmonary inflammation. (A and B) Bone marrow cells from Rev-ErbĮ–/– or littermate 
controls were transplanted into WT recipient mice, which were then exposed to aerosolized LPS at 2 mg/ml or saline at indicated times for 20 minutes. (A) 
Neutrophil numbers in BAL samples or lung digests collected 5 hours after challenge, determined by flow cytometry analyses. (B) Chemokine protein levels 
in BAL samples. Data presented as mean ± SEM; n = 2 (saline) or 5–8 (LPS), *P < 0.05, ***P < 0.001 (2-way ANOVA, post hoc Bonferroni). (C–E) Ccsp-Rev-
ErbĮ-DBDm and littermate control mice were exposed to aerosolized LPS at 2 mg/ml or saline at ZT4 for 20 minutes. (C) Total cell counts in BAL samples 
collected 5 hours after challenge. Neutrophil and macrophage numbers in the same samples were determined by flow cytometry analyses. (D) Chemokine 
protein levels in BAL samples, measured using multiplex assay. (E) qPCR analysis of Cxcl5 mRNA in lung tissues. Data normalized to saline Rev-ErbĮfl/fl 
control group. Data presented as mean ± SEM; n = 5–9, *P < 0.05, **P < 0.01, ***P < 0.001 (2-way ANOVA, post hoc Bonferroni).
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studies from global Rev-ErbĮ–null mice and from WT littermate 
controls (Figure 2, A and B, and Supplemental Figure 4A). Recip-
ient mice showed only very minor changes in the circulating 
myeloid cell pool (Supplemental Figure 4A), but we noted that 
the time-of-day variation in pulmonary neutrophilia in the lung 
digests and in BAL G-CSF was not significant in myeloid Rev-ErbĮ– 
null animals (Figure 2, A and B). In this study, we directly com-
pared the cell yields from BAL and lung digestion, as we were con-
cerned about the variance seen in some BAL experiments (Figure 
2A, left panel). Lung digestion gives more precise measurements, 
but excludes other measurements from the lung tissue, and for 
that reason we returned to BAL measures for subsequent analyses.
We next generated mice with conditional deletion of the DBD 
of Rev-ErbĮ in myeloid-lineage cells by crossing floxed (Rev-ErbĮfl/fl) 
mice (14) with a LysMCre/+ strain (LysM-Rev-ErbĮ-DBDm) on a back-
ground of PER2::Luc in order to record circadian oscillations by 
bioluminescent recording. In this model, the protein retains other 
functions but is unable to bind directly to classical REV-ERB DNA 
response elements, and thereby loses its circadian clock regulat-
ing properties (14). Peritoneal macrophages derived from these 
WTs (nonsignificant by Ȥ2 test). A slight increase in airway mac-
rophages was observed in Rev-ErbĮ–/– mice compared with litter-
mate controls (Figure 1F). There was an increase in CXCL1 in BAL 
samples from Rev-ErbĮ–/– mice exposed to cigarette smoke com-
pared with littermate controls, but no differences were observed 
for other chemokines and cytokines in BAL samples (Figure 1G), 
indicating a striking specificity of response.
Because of the lack of a robust cigarette smoke phenotype, 
and the identification of differentially regulated eosinophil 
chemokines (Supplemental Table 1; IL-5, CCL11), we analyzed 
an allergic inflammatory challenge using ovalbumin (OVA; Sup-
plemental Figure 3 and ref. 20). There were no significant differ-
ences in response between genotypes, suggesting that REV-ERBĮ 
had particular selectivity for innate rather than adaptive immune 
responses in the lung.
Targeting Rev-ErbĮ in myeloid cells impairs time-of-day varia-
tion in pulmonary neutrophilic inflammation. Both alveolar macro-
phages and the airway epithelium provide the first lines of defense 
against respiratory pathogens (21, 22). To test the role of Rev-ErbĮ 
in the myeloid lineage, we performed bone marrow transplant 
Figure 3. Both REV-ERB paralogs are required for circadian rhythms in the airway epithelium. (A) qPCR analysis of mRNA in bronchial epithelial cells, 
laser-captured from lung tissues collected at ZT9. Data normalized to Rev-ErbĮ/ȕfl/fl control group and presented as mean ± SD; n = 3, **P < 0.01, Stu-
dent’s t test. (B) qPCR analysis of mRNA in whole lung collected at ZT9. Data normalized to Rev-ErbĮ/ȕfl/fl control group and presented as mean ± SEM;  
n = 7, ***P < 0.001, Student’s t test. (C) Snapshots of PER2 oscillations in bronchioles within precision-cut lung slices. Scale bars: 500 ȝm. Biolumines-
cence intensity from bronchioles was quantified, normalized to a 24-hour moving average. Traces are representative of 2 biological replicates. (D) Biolumi-
nescence recordings of whole-lung PER2 oscillations in precision-cut lung slices. Photon counts per minute were normalized to a 24-hour moving average, 
and traces are representative of 3 biological replicates.
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mice exhibited near-total abolition of targeted Rev-ErbĮ mRNA, 
but expressed the truncated, DBD-deleted Rev-ErbĮ transcript 
(Supplemental Figure 4B), consistent with previous findings (14). 
We cultured circadian-synchronized peritoneal macrophages, and 
the targeted deletion did not impair core circadian oscillations of 
PER2::Luc bioluminescence (Supplemental Figure 4C).
We did not detect differences between the LysM-Rev-ErbĮ-
DBDm mice and littermate controls in the inflammatory response 
to aerosolized LPS at ZT4 (Supplemental Figure 4, D and E). To 
exclude the possibility that we had missed the time at which a 
difference was present, a phase shift in the response curve, we 
compared genotypes at 6-hour intervals, but again saw no differ-
ence (Supplemental Figure 4F). Further, we deleted Rev-Erbȕ in 
myeloid cells, and again saw no phenotype (Supplemental Fig-
ure 4G). From this, we conclude that REV-ERBĮ, in a non–DBD- 
dependent mechanism, in myeloid-lineage cells participates in 
conferring time-of-day variation in neutrophilic lung inflamma-
tion, but that the increased amplitude of response observed in the 
global knockouts is not seen. Therefore, we concluded that another 
cell type is required to explain the overall impact of global REV- 
ERBĮ loss, and next examined the role of the bronchial epithelium.
Targeted deletion of the DBD of Rev-ErbĮ in bronchiolar epithelial 
cells augments pulmonary inflammatory responses. We targeted bron-
chial epithelial cells by crossing Rev-ErbĮfl/fl mice with a CcspiCre/+ 
line, which is selectively expressed in pulmonary bronchoepithelial- 
lineage cells (2). As for the mutation in myeloid cells, deletion of 
REV-ERBĮ DBD in bronchial epithelial cells did not impair circa-
dian oscillations of PER2::Luc bioluminescence in the bronchioles 
(Supplemental Figure 4H). Ccsp-Rev-ErbĮ-DBDm mice exhibited a 
marked and exaggerated neutrophilic response to LPS compared 
with Rev-ErbĮfl/fl littermate controls (Figure 2C). To investigate the 
mediating pathway, we screened a panel of 23 proinflammatory 
cytokines/chemokines from BAL fluid by multiplex assay, and 
here only a single chemokine, CXCL5, was significantly increased 
in Ccsp-Rev-ErbĮ-DBDm mice, both at basal levels and following 
LPS (Figure 2D and Supplemental Table 3). RNA analyses for 
inflammatory genes in whole lung extracts also revealed marked 
specificity of response for Cxcl5 (Figure 2E). Therefore, bronchi-
al epithelial deletion of the REV-ERBĮ DBD offers a similar but 
milder phenotype compared with the global REV-ERBĮ deletion. 
The differences seen in comparing the global loss of REV-ERBĮ 
likely reflect contributions from both the epithelium and also the 
myeloid lineage, and, interestingly, while the DBD of REV-ERBĮ 
is required in the epithelium for the effect on the magnitude of 
inflammation, it is not needed within the myeloid lineage. Aero-
solized LPS challenge at ZT0 or at ZT12 further identified that 
the exaggerated inflammatory responses in Ccsp-Rev-ErbĮ-DBDm 
mice were largely confined to ZT0 (Supplemental Figure 4I and 
Supplemental Table 4).
Dual targeting of Rev-ErbĮ and Rev-Erbȕ in CCSP-expressing cells 
abolishes diurnal rhythmicity in the airway epithelium and exagger-
ates inflammatory responses. Both REV-ERBĮ and its paralog REV- 
ERBȕ are recognized as partially redundant elements driving the 
core circadian oscillator, with disruption of both genes leading to 
loss of circadian rhythmicity (13, 23), which makes them bona fide 
core clock genes. To determine the effects of possible functional 
redundancy between the REV-ERBs, both of which require BMAL1 
for expression, mice with conditional deletion of both Rev-ErbĮ 
DBD and Rev-Erbȕ in bronchiolar epithelial cells (Ccsp-Rev-ErbĮ- 
DBDm/Rev-Erbȕ–/–) were generated by breeding of Rev-ErbĮfl/fl/
Rev-Erbȕfl/fl mice with CcspiCre/+ mice, with all strains bred on a 
PER2::Luc background. Laser capture of bronchiolar epithelial 
cells from lungs collected at ZT9 confirmed the efficiency of the 
gene targeting strategy with marked reduction in the targeted exon 
transcripts, accompanied by a 12-fold increase in Bmal1 transcript 
in the double-mutant mice compared with the littermate controls 
(Figure 3A). As described in previous studies (14, 24), this led to an 
increase in transcript levels of a DBD-deleted Rev-ErbĮ transcript, 
which is translated, but no change in the expression of an exon 4–
deleted Rev-Erbȕ transcript, which is not translated, in the bronchi-
olar epithelial cells (Supplemental Figure 5A). As we had seen an 
induction of LPS response in epithelial-targeted mice, we also test-
ed for epithelial expression of the TLR4 gene, but saw no change in 
expression even in the double-mutant animals (Figure 3A).
In whole lung, we did not detect transcript changes for either 
Rev-Erb gene, but there was nonetheless a marked upregulation of 
Bmal1 mRNA, indicating loss of REV-ERB negative feedback (Fig-
ure 3B). Bioluminescent imaging of ectopic lung slices from Ccsp-
Rev-ErbĮ-DBDm/Rev-Erbȕ–/– mice showed disrupted circadian 
oscillations of PER2::Luc in the bronchioles (Figure 3C). This loss of 
rhythmicity was confined to the bronchioles, as PER2::Luc oscilla-
tions were retained elsewhere in the lung parenchyma (Figure 3D).
We next compared inflammatory responses to aerosolized 
LPS at ZT4 in Ccsp-Rev-ErbĮ-DBDm versus Ccsp-Rev-ErbĮ-DBDm/ 
Rev-Erbȕ–/– mice, with littermate controls (CCSP+/+). Double- 
mutant mice exhibited larger neutrophilic responses to LPS (2-fold), 
compared with their littermate controls (Figure 4A), than Ccsp-Rev-
ErbĮ-DBDm mice (1.4-fold; Figure 2A). Only a single chemo kine 
(CXCL5) was differentially expressed in Ccsp-Rev-ErbĮ-DBDm 
mice in response to LPS (Figure 4, B and C, and Supplemen-
tal Table 5), consistent with the previous experiments. CXCL5 
expression (both protein and transcript) was greatly increased in 
Figure 4. Loss of both REV-ERBĮ DBD and REV-ERBȕ in the airway 
epithelium further exaggerates inflammation. (A) Flow analysis of 
neutrophils in BAL samples after aerosolized LPS (2 mg/ml) at ZT4 for 20 
minutes. Data presented as mean ± SEM; n = 5–8, *P < 0.05 (Student’s t 
test). (B) Cytokine/chemokine protein levels in BAL samples after aerosol-
ized LPS or saline at ZT4 for 20 minutes. Data presented as mean ± SEM; 
n = 5–9, **P < 0.01, ***P < 0.001 (2-way ANOVA, post hoc Bonferroni). (C) 
qPCR analysis of Cxcl5 levels in lung tissues from the same mice as above. 
Data normalized to saline Rev-ErbĮfl/fl control group and presented as 
mean ± SEM; n = 5–9, ***P < 0.001 (2-way ANOVA, post hoc Bonferroni). 
(D) Neutrophil numbers in BAL samples after aerosolized LPS or saline at 
ZT4 for 20 minutes. Data presented as mean ± SEM; n = 5–9, **P < 0.01 
(2-way ANOVA, post hoc Bonferroni). (E) CXCL5 protein levels in the same 
BAL samples as above. Data presented as mean ± SEM; n = 5–9, ***P < 
0.001 (2-way ANOVA, post hoc Bonferroni). (F) Neutrophil numbers in 
BAL samples collected 5 hours after aerosolized LPS challenge at ZT0 or 
ZT12. Data presented as mean ± SEM; n = 7–9, *P < 0.05, **P < 0.01 (2-way 
ANOVA, post hoc Bonferroni). (G) Cytokine/chemokine protein levels in the 
same BAL samples as above. Data presented as mean ± SEM; n = 7–9, *P 
< 0.05, **P < 0.01, ***P < 0.001 (2-way ANOVA, post hoc Bonferroni). (H) 
qPCR analysis of Cxcl5 levels in lung tissues from the same mice as above. 
Data normalized to saline Rev-ErbĮ/ȕfl/fl control group and presented as 
mean ± SEM; n = 7–9, ****P < 0.0001 (2-way ANOVA, post hoc Bonferroni).
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at ZT12 in comparison with littermate controls (Figure 4G and 
Supplemental Table 6), indicating the impact of loss of overall 
clock control of inflammatory responses. These data suggest that 
REV-ERBĮ has evolved a specific role to couple rhythmic out-
put from the circadian clock to innate epithelial immunity, while 
REV-ERBȕ’s contribution emerges only in double knockouts, con-
ditions that also cause loss of core cellular circadian clock oscil-
lations, and therefore brings into play a greater diversity of clock 
output pathways. Importantly, we did not observe any change in 
the circulating neutrophil pool in response to airway impairment 
of both REV-ERBs (Supplemental Figure 5D). This indicates that it 
is local recruitment of neutrophils into the lung rather than disrup-
tion of neutrophil production and release into the circulation that 
explains the lung inflammatory phenotype.
Development and biological action of a novel oxazole inverse ago-
nist of REV-ERB. The availability of specific ligands permits new 
insight into nuclear receptor biology. Previous attempts to target 
the REV-ERBs have identified agonists with variable off-target 
effects on LXRs (15) and low efficacy. In pursuit of new chemical 
biology tools, we developed a specific ligand with inverse agonist 
properties: GSK3201362, hereafter referred to as GSK1362 (Fig-
ure 5A and Supplemental Figure 6A). Using an established fluo-
rescence resonance energy transfer (FRET) assay (15), recruit-
ment of comodulator peptide sequences to REV-ERBĮ protein in 
the presence of GSK1362 was determined, and compared with 
the previously reported tertiary amine agonist GSK4112 (Figure 
5B). GSK1362 inhibited interaction of the REV-ERBĮ ligand-bind-
ing domain with peptides derived from NCoR1 and SMRT2, two 
repressive comodulators, characteristic actions of an inverse ago-
nist. The interaction of a peptide derived from RIP140, a comod-
ulator for NF-ĸB/RelA–dependent cytokine gene expression, with 
REV-ERBĮ was also repressed in a dose-dependent manner. In 
contrast, the agonist compound GSK4112 promoted the recruit-
ment of NCoR1 and SMRT2 and did not regulate recruitment of 
the RIP140 peptide. The activity of GSK1362 was also compared 
with that of GSK4112 using a Bmal1 reporter assay. GSK1362 con-
centration-dependently increased transcription, while GSK4112 
caused inhibition (Figure 5C), suggesting an inverse agonist effect 
of the compound acting to relieve BMAL1 repression by endog-
enous REV-ERB ligands such as heme. To gain additional infor-
mation on GSK1362 engagement with REV-ERBĮ protein, we 
established a cellular thermal shift assay (CETSA), which revealed 
a change in REV-ERBĮ protein stability resulting from GSK1362 
exposure (Supplemental Figure 6B). CETSA is a simple, robust, 
and agnostic assay, which reports changes in protein structure 
induced by ligand binding (25). A model for GSK1362 bound to 
REV-ERBĮ was constructed from the crystal structure of REV- 
ERBĮ bound to NCoR ID1 (26) (pdb 3N00) (Figure 5D). Key REV-
ERB interactions with the ligand are driven by the highly hydropho-
bic ligand-binding domain of the protein and include the terminal 
4-chlorobenzyl group flanked by Phe433 and Phe477 along with 
the central aromatic ring interacting with Val447. The O-methyl 
ethanolamine side chain of the oxazole proved crucial for activity, 
which could interact through a key hydrogen bond with Lys473. 
Importantly, GSK1362 lacked the LXR activity that was seen in 
first-generation REV-ERB ligands, as it failed to induce expression 
of the known LXR target genes Abca1 and Abcg1 (Figure 5E).
Ccsp-Rev-ErbĮ-DBDm/Rev-Erbȕ–/– mice, as was the cellular inflam-
matory reaction to LPS. In these double-mutant mice, in addition 
to CXCL5, we also observed augmentation of CXCL1, CXCL2, 
and G-CSF production (Figure 4B) — the same 4 chemokines that 
showed altered expression in the global Rev-ErbĮ–null mice. Fur-
ther, in Ccsp-Rev-ErbĮ-DBDm/Rev-Erbȕ–/– mice we also observed 
significantly increased CXCL5 in unchallenged conditions, equiv-
alent to that seen in control Rev-ErbĮ/ȕfl/fl littermate mice exposed 
to LPS (Figure 4B). In situ hybridization of lung sections from 
unchallenged mice demonstrated that enhanced Cxcl5 expres-
sion in Ccsp-Rev-ErbĮ-DBDm/Rev-Erbȕ–/– mice was confined to 
the bronchioles (Supplemental Figure 5B), the same structures 
showing Rev-Erb gene disruption, whereas we did not observe any 
change in systemic levels of CXCL5 (Supplemental Figure 5C).
The exaggerated inflammatory response observed in the double- 
mutant animals compared with mice with only mutation of REV- 
ERBĮ DBD could be the consequence of either an additive con-
tribution of REV-ERBȕ or dysregulation of the clock machinery in 
the bronchioles, the result of disruption to both Rev-Erb genes. To 
answer that question, we generated mice with conditional deletion 
of only REV-ERBȕ in bronchiolar epithelial cells (Ccsp-Rev-Erbȕ–/–) 
and exposed these animals and their littermate controls (Rev-Erbȕfl/fl) 
to an aerosolized LPS challenge at ZT4. Both groups exhibited sim-
ilar inflammatory responses (Figure 4, D and E). This suggests that 
Rev-ErbĮ plays the dominant role in regulation of epithelial immunity 
in the lung, and furthermore that the more severe inflammatory phe-
notype observed in the double mutant is a likely consequence of a 
major disruption of circadian timing in these cells.
Further analysis of the double-mutant mice by time of day 
revealed exaggerated neutrophilic inflammation at both ZT0 
and ZT12 (Figure 4F). The differences were most pronounced 
for CXCL5 for both the secreted chemokine and mRNA expres-
sion (Figure 4, G and H, and Supplemental Table 6), but smaller 
differences were also observed for CXCL1, CXCL2, and G-CSF 
Figure 5. REV-ERBĮ ligand GSK1362 represses inflammatory genes in 
macrophages and epithelial cells and stabilizes REV-ERBĮ protein. (A) 
Chemical structure of GSK1362. (B) Effect of GSK1362 and GSK4112 on 
peptide fragment recruitment to REV-ERBĮ. (C) Cotransfection of HEK293 
cells with HA–Rev-ErbĮ and Bmal1-Luc reporter. Cells were treated with 
GSK1362 or GSK4112 at different concentrations for 24 hours before lucifer-
ase assay. Values plotted relatively to 0.1% DMSO; error bars indicate mean 
± SD. Data representative of n = 3. (D) Models showing GSK1362 docked 
in REV-ERBĮ ligand-binding domain. (E) qPCR analysis of LXR target 
genes in peritoneal exudate cells treated ex vivo with GSK1362 at 10 ȝM 
or GW3965, a standard LXR agonist, at 2 ȝM for 4 hours. Data presented 
as mean ± SD; n = 3, ***P < 0.001 (1-way ANOVA, post hoc Bonferroni). (F) 
qPCR analysis of cytokine mRNA in alveolar macrophages collected at ZT8, 
seeded into plates and directly treated with GSK1362 at 10 ȝM in the pres-
ence or absence of LPS at 100 ng/ml for 4 hours. Data presented as mean 
± SD; n = 3, *P < 0.05, **P < 0.01 (1-way ANOVA, post hoc Bonferroni). 
(G) qPCR analysis of Cxcl5 in LA-4 cells synchronized by serum shock and 
treated 16 hours later with ligands at 10 ȝM, followed 2 hours later by IL-1ȕ 
at 1 ng/ml for 2 additional hours. Data normalized to unstimulated control 
cells and presented as mean ± SD; representative of n = 3, **P < 0.01, 
***P < 0.001 (2-way ANOVA, post hoc Bonferroni). (H) REV-ERBĮ protein 
in LA-4 cells synchronized by serum shock and treated 16 hours later with 
ligands at 10 ȝM for 4 hours. Representative of n = 3. (I) REV-ERBĮ protein 
in NHBE cells synchronized by serum shock and treated 16 or 28 hours later 
with ligands at 10 ȝM for 4 hours. Representative of n = 3.
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mental Table 7). Therefore, we 
add to evidence that GSK1362 
acts through REV-ERBĮ, but 
GSK1362 cannot be regarded as 
a chemical probe, as it may have 
additional targets, which remain 
to be defined.
Extending our analysis 
to bronchial epithelial cells, 
GSK1362 inhibited Cxcl5 tran-
script induction in mouse LA-4 
cells, as did, to a lesser extent, 
the REV-ERB natural ligand 
hemin (Figure 5G), providing an 
additional line of evidence that 
Cxcl5 is a REV-ERB target gene 
in airway epithelial cells. In con-
trast, the REV-ERB ligands had 
no major effect on other inflam-
matory genes (Supplemental Fig-
ure 7B). Unfortunately, despite 
exhaustive efforts and trying 
multiple antibodies, we were not 
successful in determining high- 
confidence ChIP-Seq results for 
endogenous REV-ERBĮ in LA-4 
cells, which would have helped us 
to uncover potential recruitment 
of REV-ERBĮ to the Cxcl5 gene 
promoter or enhancer regions in 
airway epithelial cells.
While these studies of REV-
ERB ligand action were under 
way, we noted a marked increase 
in REV-ERBĮ protein abundance 
with all ligands tested, but, more 
importantly, with the novel 
ligand GSK1362 (Figure 5H). This 
was also seen in human prima-
ry bronchial epithelial (NHBE) 
cells, which have intact circadian 
REV-ERBĮ oscillations (Figure 5I 
and Supplemental Figure 7, C and 
D). However, in NHBE cells, the 2 REV-ERB ligands GSK1362 and 
GSK4112 had complex and divergent effects on multiple proin-
flammatory cytokines upon IL-1ȕ stimulation (Supplemental Fig-
ure 7E), again emphasizing the critical role of cell type–specific 
factors in determining the action of REV-ERBs, the limitations of 
REV-ERBs as drug targets for inflammatory diseases, and import-
ant differences in response between cell types.
Rapid degradation of REV-ERBĮ protein is mediated by inflam-
matory stimuli, and reversed by the inverse agonist GSK1362. While 
studies have highlighted the importance of the clock in modulation 
of inflammation, there is evidence that this connection is bidirec-
tional and the inflammatory response itself can affect molecu-
lar clock pathways (28, 29). As REV-ERB ligands both repressed 
inflammatory responses and increased REV-ERBĮ protein concen-
We previously demonstrated that the REV-ERB agonist 
GSK4112 inhibited cytokine production from activated macro-
phages (5). We were therefore surprised to discover that REV-ERB 
inverse agonist GSK1362 also inhibited LPS induction of several 
inflammatory cytokines from alveolar macrophages (Figure 5F). 
In bone marrow–derived macrophages, GSK1362 inhibited Il-6 
gene expression in a REV-ERBĮ–dependent manner (Supplemen-
tal Figure 7A), but had no effect on Ccl2, Cxcl1, or Cxcl2, high-
lighting the complex effects of REV-ERB ligands. We also used 
the previously described REV-ERBĮ antagonist SR8278 (27), and 
found that this had no effect on Il-6. These studies do not exclude 
the possibility of further off-target effects of the GSK1362 ligand; 
therefore, we screened GSK1362 against a panel of 20 nuclear 
receptors, which did not reveal any significant activity (Supple-
Figure 6. Inflammatory stimuli promote REV-ERBĮ degradation. (A) Whole-lung REV-ERBĮ protein in WT mice 
2 or 4 hours after aerosolized LPS (2 mg/ml) or saline solution for 20 minutes at CT8 (see Methods). REV-ERBĮ 
densitometry (mean ± SEM) was normalized to ȕ-actin and to saline at 2 hours; n = 6, *P < 0.05, **P < 0.01 
(1-way ANOVA, post hoc Bonferroni). (B) Whole-lung REV-ERBĮ protein in mice after aerosolized LPS (2 mg/
ml) or saline solution for 20 minutes at ZT4 for 5 hours. REV-ERBĮ densitometry (mean ± SD) was normalized 
to ȕ-actin and to group 1; n = 3, ***P < 0.001 (2-way ANOVA, post hoc Bonferroni). (C) REV-ERBĮ protein in 
NHBE cells synchronized by serum shock and treated 18 hours later with TNF-Į or IL-1ȕ at 10 ng/ml for 1 hour. 
(D) REV-ERBĮ protein in NHBE cells synchronized by serum shock and treated 18 hours later with GSK1362 or 
DMSO at 10 ȝM followed 15 minutes later by cycloheximide (CHX) at 10 ȝM and IL-1ȕ at 1 ng/ml. Cells were lysed 
at different times as indicated. (E) REV-ERBĮ protein in SW1353 cells synchronized by serum shock and treated 
23 hours later with kinase inhibitors for 30 minutes followed by IL-1ȕ at 5 ng/ml for 1 hour. (F) REV-ERBĮ protein 
in SW1353 cells synchronized by serum shock and treated 23 hours later with PBS, TNF-Į, or IL-1ȕ at 5 ng/ml for 1 
hour in the absence and presence of MG132 at 5 ȝM. All blots are representative of at least n = 3.
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some inhibitor MG132 (Figure 6F), identifying the 26S proteasome 
as promoting rapid REV-ERBĮ protein degradation.
Posttranslational mechanisms are required for REV-ERBĮ degra-
dation, and are blocked by the inverse agonist GSK1362. Posttrans-
lational modifications such as phosphorylation, SUMOylation, 
and ubiquitination constitute an important regulatory system in 
nuclear receptor function. The rapid, proteasomal degradation of 
REV-ERBĮ induced by inflammatory cytokine action suggests a 
ubiquitination step. Indeed, REV-ERBĮ was rapidly ubiquitinated 
in response to either IL-1ȕ or TNF-Į action, an effect blocked by 
GSK1362 (Figure 7A). Interestingly, ubiquitination of REV-ERBĮ 
upon IL-1ȕ treatment was also prevented by the CDK inhibitor 
tration, the effect of inflammation on REV-ERBĮ protein was deter-
mined. Previous reports support inhibition of REV-ERBĮ transcrip-
tion by inflammation (11, 30), but here we observed very rapid loss 
of REV-ERBĮ protein in inflamed lung tissue (Figure 6A). We also 
found that the REV-ERBĮ protein lacking its DBD also showed 
such degradation, again in lung tissue (Figure 6B). This was mim-
icked by inflammatory cytokine action in vitro (Figure 6C), and was 
opposed by GSK1362 (Figure 6D). Therefore, GSK1362 stabilizes 
REV-ERBĮ protein, identifying an important site of inflammatory/
circadian crosstalk, an effect mediated, in part, by inflammatory 
activation of p38 MAP kinase (Figure 6E). REV-ERBĮ protein lev-
els were greatly increased when cells were treated with the protea-
Figure 7. Requirement of posttranslational modifications for REV-ERBĮ degradation. (A–C) Ubiquitinated REV-ERBĮ protein in HEK293T cells transfect-
ed with HA–Rev-ErbĮ, His-Ub, and SENP-1 plasmids and treated with GSK1362 at 10 ȝM, roscovitine at 25 ȝM, and TNF-Į or IL-1ȕ at 5 ng/ml for 4 hours 
in the presence of MG132 at 5 ȝM. (D–G) SUMO-2 ligation to REV-ERBĮ protein in HEK293T cells transfected with HA–Rev-ErbĮ, His-SUMO2, Ubc9, and 
SENP-1 plasmids and treated with GSK1362 at 10 ȝM and kinase inhibitors and IL-1ȕ or TNF-Į at 5 ng/ml for 4 hours in the presence of MG132 at 5 ȝM. (H) 
Coimmunoprecipitation of HDAC3 and REV-ERBĮ protein in HEK293T cells transfected with HA–Rev-ErbĮ and SENP-1 plasmids and treated with GSK1362 
at 10 ȝM and IL-1ȕ at 5 ng/ml for 4 hours. All blots are representative of at least n = 3.
The Journal of Clinical Investigation R E S E A R C H  A R T I C L E
2 2 9 2 jci.org   Volume 128   Number 6   June 2018
effect on pulmonary neutrophilic inflammation, with attenuation 
of the time-of-day variation. In these studies, we compared anal-
ysis of BAL with lung digest, as a means to recover immune cells 
from inflamed lung, and confirmed that the digest offers a more 
precise assay. Indeed, we only observed the loss of time-of-day 
variation in lung digest analysis.
Mutation of the REV-ERBĮ DBD in myeloid cells had no impact 
on pulmonary inflammatory responses in our in vivo model, which 
was unexpected, both because isolated alveolar macrophages 
lacking REV-ERBĮ show exaggerated LPS responses ex vivo, and 
because complete loss of REV-ERBĮ did have a phenotype. There-
fore, we conclude that the REV-ERBĮ effect in myeloid cells is 
exerted through a non–DBD-dependent mechanism, akin to that 
documented in the liver, where DBD-independent control of lipid 
metabolism was seen to dissociate from the clock-regulating func-
tions of REV-ERBĮ, which require binding to consensus REV-ERB 
cis elements (14). Deletion of REV-ERBȕ in the myeloid lineage did 
not result in a lung inflammatory phenotype. In contrast, muta-
tion of REV-ERBĮ DBD in bronchiolar epithelial cells resulted in 
increased neutrophilia and CXCL5 levels. This suggests a promi-
nent conditioning role for the airway epithelial cells in vivo and 
indicates that REV-ERBĮ in bronchiolar epithelial cells possesses 
an antiinflammatory function, which is operated by its ability to 
bind DNA. Mice with complete loss of REV-ERBĮ in bronchiolar 
epithelial cells are not yet available but would be particularly useful 
to determine a potential non–DNA-binding effect of REV-ERBĮ in 
the airway epithelium upon gating of the inflammatory responses, 
similar to the effect observed in REV-ERBĮ–null myeloid cells.
As both REV-ERBĮ and REV-ERBȕ show major physiological 
redundancy, the question of REV-ERBȕ function required analy-
sis. Using a double-mutant mouse model, we found a significant 
compensatory role for REV-ERBȕ, with greatly exaggerated LPS 
responses, involving more chemokines, and also, intriguingly, 
leading to augmented CXCL5 production under basal conditions. 
However, we discovered that the REV-ERBĮ paralog is dominant 
over the REV-ERBȕ, which could be deleted in the bronchial epi-
thelium without a resulting inflammatory phenotype.
There has been great interest in understanding how the circa-
dian clock affects immunity (7, 8, 32). BMAL1 deletion in the pul-
monary epithelium blocks circadian control of inflammation, and 
augments the inflammatory response. BMAL1 plays many roles in 
development beyond its circadian function, and indeed postnatal 
BMAL1 loss results in a far milder phenotype than constitutive 
deletion (33). Some studies have revealed a direct role for BMAL1 
acting to regulate NF-ĸB function either through enzymatic modi-
fication (9) or through regulation of microRNA (10). In our current 
study, we show that functional disruption/deletion of the 2 REV-
ERB paralogs is proinflammatory, despite a massive increase in 
BMAL1 expression, with the same CXCL neutrophil chemo kines 
and G-CSF emerging as key inflammatory mediators. These new 
data demonstrate a functionally important pathway from the core 
clock through REV-ERBĮ to regulate pulmonary inflammation. 
However, further studies will be required to establish with high 
confidence REV-ERBĮ cistrome in airway epithelial cells and 
uncover relevant transcriptional mechanisms.
Functional analysis of nuclear receptors can be greatly accel-
erated by use of regulating ligands, and previous attempts to tar-
roscovitine (Figure 7B), suggesting that the CDK1/FBXW7 path-
way targeting REV-ERBĮ, described in previous studies (31), is 
activated by inflammatory cytokines. In addition to CDK inhibi-
tion impairing ubiquitination, the SUMO protease SENP-1 was 
also highly effective (Figure 7C), indicating that SUMOylation is 
a requirement for REV-ERBĮ ubiquitination, and prompting fur-
ther investigation into REV-ERBĮ SUMOylation, which revealed 
Ubc9-dependent SUMO-2 ligation (Figure 7D). IL-1ȕ promot-
ed SUMO-2 ligation to REV-ERBĮ, whereas ligand GSK1362 
blocked it (Figure 7E), and again inhibition of CDKs with rosco-
vitine blocked SUMOylation (Figure 7F), supporting a pathway of 
phosphorylation followed by SUMO-dependent ubiquitination. 
As we had identified p38 inhibition to block inflammatory cyto-
kine–driven REV-ERBĮ degradation, we looked for a p38 role in 
SUMOylation also, and indeed showed that p38 inhibition, but not 
JNK inhibition, reduced REV-ERBĮ SUMOylation (Figure 7G).
Inflammatory signaling also drove a SUMOylation-depen-
dent recruitment of HDAC3 to REV-ERBĮ, an effect that was not 
disturbed by GSK1362 ligand binding (Figure 7H). The failure of 
ligand binding to regulate HDAC3 recruitment suggests that the 
principle mechanism of ligand action to suppress inflammatory 
cytokine expression is by stabilizing the REV-ERBĮ protein under 
conditions favoring rapid degradation. We attempted to localize 
the modified lysine in REV-ERBĮ using a mutagenesis approach, 
but were not able to identify a single, dominant lysine. We consid-
er it likely that the REV-ERBĮ protein is multiply modified, with 
a complex code including phosphorylation, SUMOylation, and 
SUMO-dependent ubiquitination.
Analysis of REV-ERBȕ modification, in contrast, revealed 
only a very minor increase in ubiquitination in response to IL-1ȕ 
(Supplemental Figure 8A), and we could not detect SUMOylation 
under any circumstance (Supplemental Figure 8B). This again fits 
with the divergence of function, with REV-ERBĮ playing the dom-
inant role in this signaling circuit.
Discussion
The circadian clock plays a vital role in coordinating many phys-
iological programs across tissues in anticipation of predictable 
changes in the environment, principally day-night. The role of 
such biological timing mechanisms in inflammation and immuni-
ty is being defined now, with the most prominent phenotypes cen-
tering on macrophages and innate immunity. We have previously 
defined the role of BMAL1, the only essential core clock compo-
nent for cell-autonomous oscillations, in pulmonary inflamma-
tion and immunity. Moreover, we defined a surprising dominant 
role for timing circuits in the airway epithelium, rather than in 
the myelomonocytic lineage, by disrupting BMAL1 in these cells. 
However, the role of BMAL1 versus loss of timing, and the down-
stream pathways regulating inflammatory signaling, remained 
key unanswered questions. We now identify a highly specific 
circuit requiring the nuclear receptor and tractable drug target 
REV-ERBĮ that mediates the BMAL1 effect within bronchial epi-
thelial cells to regulate pulmonary inflammation.
Global loss of REV-ERBĮ resulted in exaggerated pulmonary, 
innate immune responses with loss of the normal evening nadir in 
inflammatory response to LPS. Analysis of the myeloid cell pop-
ulation revealed that complete loss of REV-ERBĮ had a modest 
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propose that REV-ERBĮ degradation by inflammatory signaling 
offers a new pathway to explain circadian disruption in chronic 
inflammatory disease, and the REV-ERBĮ stabilization seen with 
ligand binding offers a new mechanism for REV-ERBĮ function-
al regulation. In addition, the emerging role of REV-ERBĮ as a 
cell type–specific mediator of timing information and control of 
inflammatory response gives new insights into an ancient host- 
defense control system.
Methods
Animals. Nr1d1tm1Schb mice with global Rev-ErbĮ knockout (subsequent-
ly known as Rev-ErbĮ–/–) were provided by Ueli Schibler (University 
of Geneva, Geneva, Switzerland) (16). These animals were bred as a 
heterozygous colony, and offspring genotyped to identify knockout 
and WT animals. Conditional club cell or myeloid cell Rev-ErbĮ-DBD 
mutant mice (Ccsp-Rev-ErbĮ-DBDm or LysM-Rev-ErbĮ-DBDm) were 
generated by breeding of Rev-ErbĮfl/fl mice (Nr1d1tm1Ics; Institut Clinique 
de la Souris, Illkirch, France) with Ccsp-iCre (36) or LysM-Cre mice. 
Similarly, conditional club cell Rev-ErbĮ-DBD mutant and Rev-Erbȕ–
knockout mice (Ccsp-Rev-ErbĮ-DBDm/Rev-Erbȕ–/–) were generated by 
breeding of Rev-Erbȕfl/fl mice (Nr1d2tm1.1Rev; Institut Clinique de la Souris) 
with Ccsp-Rev-ErbĮ-DBDm mice. Tissue expression of iCre (CCSP) or 
Cre (LysM) was assessed by reverse transcriptase PCR as described 
elsewhere (2, 5). All mouse lines were subsequently crossed onto a 
PER2::Luc background (37). All animals were housed in a 12-hour 
light/12-hour dark schedule with food and water available ad libitum. 
In all studies, both male and female mice were used (age 6–12 weeks).
Aerosolized LPS challenge. In vivo LPS challenge was undertaken 
as described previously (2). In brief, animals were exposed to an aero-
sol of LPS (E. coli 0127:B8; Sigma-Aldrich) at doses ranging from 0.05 
mg/ml to 2 mg/ml for 20 minutes. Animals were sacrificed 5 hours 
later. Bronchoalveolar lavage (BAL) was performed by instillation and 
removal of 1 ml aliquot of BAL fluid (10 mM EDTA in PBS with 0.1% 
BSA) administered via a tracheal cannula. Lung tissues were collected 
and snap-frozen on dry ice or were filled with paraformaldehyde and 
removed for histological analysis. Challenges at ZT0 and ZT4 were 
performed under normal light, whereas exposures at ZT12 were per-
formed in constant darkness, using infrared goggles to view animals. 
Circadian time (CT) refers to time points under continuous darkness, 
with CT0 the start of the biological day, and CT12 the start of the bio-
logical night, and activity period in mice.
Smoke exposure. Cigarette smoke exposure was performed as 
previously described (38). Briefly, mice received a daily 2-hour nose- 
only exposure to 4% cigarette smoke from 3R4F cigarettes (College 
of Agriculture, Reference Cigarette Program, University of Kentucky, 
Lexington, Kentucky, USA). During exposure to smoke or air only 
(sham controls), mice were maintained in restraining tubes containing 
stainless steel nose cone inserts. BAL samples and lung tissues were 
collected as previously described.
Bone marrow transplant study. Recipient mice (B6 Cd45.1, Pep 
Boy; The Jackson Laboratory) were placed on Baytril antibiotic (Sigma- 
Aldrich) for 2 weeks before and 4 weeks after radiation exposure. 
Donor mice (Rev-ErbĮ–/– or littermate controls) were culled by cervi-
cal dislocation, and femurs/tibiae were removed. Bone marrow was 
flushed out using Iscove’s Modified Dulbecco’s Media (supplemented 
with 2% FCS) and suspended in red blood cell lysis buffer (Roche). 
The remaining cells were depleted of T cells using a CD90.1 Positive 
get REV-ERB have been promising. However, early-generation 
ligands had significant LXR liability, prompting us to develop a 
new compound with no LXR action, but with a unique pattern of 
comodulator peptide recruitment. In vitro, GSK1362 promoted 
disruption of repressor peptide interaction and so is an inverse 
agonist, an activity supported by divergent effects on Bmal1 
promoter regulation in comparison with GSK4112, an agonist. 
GSK1362 was tested on both isolated macrophages and bronchi-
al epithelial cells, with divergent and complex results, some of 
which may result from off-target actions. We screened GSK1362 
against a 20–nuclear receptor panel, and found negligible activi-
ty. We also used a CETSA assay to gain additional information on 
engagement with REV-ERBĮ. Our sufficiency studies were neces-
sarily limited in scope, but provided evidence that REV-ERBĮ was 
required for regulation of Il-6, a well-characterized REV-ERBĮ tar-
get gene in macrophages. Therefore, GSK1362 is a useful chemical 
tool, capable of binding to REV-ERBĮ and regulating its function. 
However, we do not claim GSK1362 has all the criteria for use as a 
chemical probe for REV-ERBĮ.
While investigating the mechanism of GSK1362 action we 
discovered a surprising ligand-dependent increase in REV-ERBĮ 
protein, suggesting that the observed chemokine repression seen 
with the ligand may in part be due to increased abundance of the 
repressor REV-ERBĮ protein.
We discovered that inflammation promotes degradation of 
REV-ERBĮ protein, through SUMO-dependent ubiquitination 
of the protein and involvement of CDKs and p38 MAP kinase. 
Strikingly, the inflammation-driven modification of REV-ERBĮ 
was efficiently blocked by GSK1362, which therefore resulted in 
an increase in REV-ERBĮ protein, and more efficient inflamma-
tory mediator gene repression. Unfortunately, GSK1362 cannot 
be used in vivo because of adverse predicted PK characteristics. 
GSK1362 is therefore a useful chemical biology tool for interrogat-
ing REV-ERBĮ function, but whether it will be possible to make 
a useful human therapeutic targeting REV-ERB remains an open 
question. In vivo effects of other REV-ERBĮ ligands have been 
reported (34, 35), but these recent studies did not compare the 
effects in REV-ERBĮ–null mice, making it impossible to attribute 
the phenotypes observed to a specific action on REV-ERBĮ.
Taken together, our data illuminate a new circuit lying between 
the core circadian clock and inflammation, with both major net-
works converging on REV-ERBĮ protein, an obligate repressor of 
aspects of the pulmonary inflammatory response. Identification of 
REV-ERBĮ degradation as a robust early response to inflammation 
supports a homeostatic role in determining the inflammatory set 
point, limiting inflammatory activity under resting, nonstress con-
ditions, as evidenced by the high basal production of chemokines 
in the bronchial epithelium of double-mutant mice (Supplemen-
tal Figure 9). REV-ERBĮ has been proposed as a tractable drug 
target for metabolic disease, and also possibly for inflammatory 
disease. The highly variable target gene responses seen with the 
new ligand suggest that any such therapeutic development would 
require careful consideration, not least as the pattern of response 
differs between cell types. However, targeting of the bronchial epi-
thelium is tractable via an inhalation approach, although the fail-
ure of REV-ERBĮ disruption to impact on allergic inflammation, 
the major human disease burden, would temper enthusiasm. We 
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py system fitted with a cooled Hamamatsu C9100-13 EM-CCD camera 
(Olympus) as previously described (40). Individual regions of interest 
were delineated using ImageJ software (version 1.41o; NIH).
Peptide recruitment profiles. These experiments were undertaken 
as previously described (15).
Bmal1 luciferase assay. HEK293 cells were transfected with 
HA-tagged Rev-ErbĮ, a luciferase reporter driven by the Bmal1 pro-
moter, and a ȕ-galactosidase reporter using polyethylenimine (PEI) 
(3:1 vol/wt ratio) (41) and left overnight. Cells were treated with 
GSK1362 at different concentrations or with 0.1% DMSO for 24 hours 
followed by the luciferase assay using the Dual-Light Luciferase and 
ȕ-Galactosidase Reporter Gene Assay System (Thermo Fisher Scien-
tific) according to the manufacturer’s instructions. Luciferase activity 
was normalized to ȕ-galactosidase reading for each sample.
His purification. HEK293 cells were transfected with 0.5 ȝg 
HA-tagged Rev-ErbĮ, 0.75 ȝg His-ubiquitin, 0.75 ȝg His–SUMO-2, 0.5 
ȝg SENP-1, and 0.25 ȝg Ubc9 using PEI (3:1 vol/wt ratio) (41) and left 
overnight. Cells were treated with 5 ȝM MG132 (Sigma-Aldrich), 10 
ȝM GSK1362 ligand, IL1-ȕ, or TNF-Į as indicated. Cells were lysed in 
either RIPA buffer (50 mM Tris-Cl pH 7.4, 1% NP-40, 0.25% sodium 
deoxycholate, 150 mM NaCl, 1 mM EDTA) supplemented with prote-
ase and phosphatase inhibitors for input samples or guanidinium/HCl 
buffer I (6 M guanidinium/HCl, 0.1 M Na
2
HPO
4
/NaH
2
PO
4
, 0.01 M 
Tris, pH8) for His-purified samples. Lysates for His purification were 
first sonicated using EpiShear Probe Sonicator and cell debris cleared 
by centrifugation. Supernatants were added to Ni-NTA Agarose beads 
(Qiagen), previously washed with buffer I and partially bound with BSA 
at 50 ng/ȝl (Sigma-Aldrich). Imidazole (5 mM) and ȕ-mercaptoethanol 
(10 mM) were also added, and samples were incubated by rotation at 
room temperature for 2–3 hours. Beads were washed twice with buffer 
I supplemented with 5 mM imidazole (rotation at room temperature for 
20 minutes followed by centrifugation at 400 g for 2 minutes to remove 
supernatant). Beads were then washed with urea buffer II (8 M urea, 0.1 
M Na
2
HPO
4
/NaH
2
PO
4
, 0.01 M Tris, pH 6.3) containing 5 mM imidaz-
ole (rotating for 10 minutes), followed by another wash with buffer II 
containing 5 mM imidazole and 0.2% Triton X-100 (Sigma-Aldrich). 
Beads were finally washed with PBS, and after centrifugation at 100 g, 
supernatants were discarded. Beads were mixed with SDS loading dye 
containing 10% ȕ-mercaptoethanol and boiled 10 minutes at 70°C. 
Samples were stored at –80°C until run for Western blotting.
Immunoprecipitation. HEK293 cells were transfected with 1 ȝg 
HA-tagged REV-ERBĮ and/or 1 ȝg SENP-1 using PEI (3:1 vol/wt ratio) 
and left overnight. Cells were treated with 10 ȝM GSK1362 ligand 
and/or 5 ng/ml IL-1ȕ for 4 hours. Cells were lysed in either RIPA buf-
fer supplemented with protease and phosphatase inhibitors for input 
samples or IP lysis buffer (150 mM NaCl, 20 mM Tris-HCl, 10% glyc-
erol, 1% Triton X-100, 1 mM PMSF, 10 mM N-ethylmaleimide (NEM), 
PhosSTOP (MilliporeSigma), complete EDTA-free protease inhibitor 
cocktail) on ice and cell debris cleared by centrifugation. One micro-
gram of anti-HDAC3 antibody (Santa Cruz Biotechnology H-99) or 
1 ȝg of rabbit IgG was incubated with protein lysates for 1 hour on a 
rotating wheel at 4°C. Antibody complexes were captured by addition 
of beads (MagReSyn Protein A; ReSyn Biosciences) for 45 minutes at 
4°C. Beads were washed 3 times with IP lysis buffer, and then boiled 
for 10 minutes in SDS loading dye containing 10% ȕ-mercaptoetha-
nol. Beads were cleared using magnetic separator, and supernatants 
were ready for electrophoresis.
Selection Kit (EasySep). Remaining donor cells were counted and 
resuspended to 2 × 107 such that each mouse received a tail vein injec-
tion of 4 × 106 cells in 200 ȝl. Recipient mice were then given 2 doses 
of radiation of 5.5 Gy separated by 2 hours. Recipient mice then had 
200 ȝl of donor cells injected into the tail vein. Mice were weighed 
daily after injections and left for 3 months to allow for full immune 
reconstitution prior to aerosolized LPS exposure.
BAL cytokine analysis, cell counts, and flow cytometry. BAL samples 
were centrifuged and the supernatant utilized for cytokine and chemo-
kine analysis using the Magnetic Luminex Assay (R&D Systems). The 
cell pellets were resuspended in 200 ȝl PBA (PBS with 1% BSA and 
0.1% sodium azide) for subsequent total cell count and analysis by 
flow cytometry. In brief, 19 ȝl resuspended cells were mixed with 1 ȝl 
of fluorescent dye solution 18 (ChemoMetec), and total cell number 
was assessed using NucleoCounter NC-250 (ChemoMetec). Frequen-
cy of neutrophils and macrophages was assessed by flow cytometry 
using anti–Ly-6G (Gr-1)–Alexa Fluor 488 and anti-CD11c–APC anti-
bodies to detect neutrophils and alveolar macrophages, respectively 
(2). For flow cytometry analyses on lung digests, the left lobe of the 
lung was placed in 1 ml RPMI (Sigma-Aldrich) containing Liberase 
(Sigma-Aldrich) and DNase I (Promega) and chopped up with scissors. 
The homogenate was placed at 37°C for 30 minutes on an orbital shak-
er. Digestion was stopped with the addition of 1 ml RPMI containing 
10 mM EDTA (Sigma-Aldrich). Homogenate was passed through a 
70-ȝm sieve (Corning) and cells pelleted at 300 g for 5 minutes at 4°C. 
Pellets were resuspended in red blood cell lysis buffer. Remaining cells 
were pelleted, counted, and plated at 1 × 106 cells for flow cytometry.
Bronchiolar epithelial cell laser capture. The trachea was cannulated 
postmortem and lungs inflated with 1 ml PBS/OCT mixture (1:1). The 
trachea was tied off, and the lungs and heart were removed en bloc 
and snap-frozen. Ten-micrometer sections were cut on the cryostat, 
and 3–4 sections were placed per polyethylene naphthalate (PEN) 
membrane slide (3 slides per animal). Before laser dissection, speci-
men slides were taken out of dry ice and placed into alcoholic solutions 
(100% ethanol for 1 minute, 75% ethanol 3 dips, 50% ethanol 3 dips, 
95% ethanol 30 seconds, 100% ethanol 30 seconds, 100% ethanol 2 
minutes). A Leica LMD 6500 laser-capture microdissection machine 
was used to cut regions around the bronchiolar airways. For tissue col-
lection, 0.5-ml thin-wall PCR tubes were used in the tissue collector, 
with 30 ȝl lysis buffer (TRK buffer supplemented with ȕ-mercaptoeth-
anol, MicroElute Total RNA kit; Omega Bio-tek). Samples were then 
stored at –80°C prior to RNA extraction using MicroElute Total RNA 
kit, following the manufacturer’s instructions.
Lung histology. Paraformaldehyde-fixed lung tissue was processed 
and embedded, and 5-ȝm sections were mounted onto slides. Sections 
were used for routine H&E staining. Immunohistochemical staining 
was carried out using antibody raised against NIMP/R14 (to detect 
neutrophils; Abcam Ab2557); sections were counterstained with 
hematoxylin. Slides were viewed using a Leica DM2000 microscope 
and images captured using a Leica IC90E digital camera and software.
Ectopic lung slices. Precision-cut ectopic lung slices (275 ȝm) were 
prepared as previously described (39). After washes to remove residu-
al agarose, slices were placed onto cell culture inserts (Millicell) with-
in 35-mm dishes containing 1 ml recording medium and sealed with a 
coverslip. Dishes were then transferred to a 37°C incubator housing the 
photomultiplier tubes (PMTs; H6240 MOD1; Hamamatsu Photonics) or 
placed under a self-contained Olympus LV200 luminescence microsco-
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Additional methods are described in Supplemental Methods online.
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Generation of REV-ERBĮ monoclonal antibody. The GSK6F05-2 
antibody (Biocat 137359) was generated by conventional 3-month 
immunization of SJL mice, with His-tagged Rev-ErbA Į ligand-bind-
ing domain (aa 281–614), purified from E. coli. Protein-specific mono-
clonal antibodies were identified by ELISA and Western blot screen-
ing of single-cell-derived clones.
CETSA assay. HEK293 cells were transfected with HaloTag- 
Rev-ErbĮ (as described above, 10 ȝg plasmid per 10-cm dish). Cells 
were treated with GSK1362 or DMSO (0.1% vol/vol) for 1 hour before 
the media was replaced with 1 ml PBS (containing protease inhibitor 
cocktail). One-hundred-microliter aliquots of cells (prepared without 
further washing in PBS) were heated (from 40°C to 58°C using a ther-
mocycler) for 3 minutes and then incubated at room temperature for 
a further 3 minutes. Following 2 freeze-thaw cycles (using dry ice, and 
a thermocycler at 25°C), 2 microliters of 10% (vol/vol) Triton X-100 
was added and the lysate vortexed. Cell lysates were centrifuged at 
20,000 g for 20 minutes (4°C) to pellet insoluble cell debris. Super-
natants were incubated with Halo-ligand (Alexa Fluor 660; Promega) 
for 15 minutes at room temperature before 4× lithium dodecyl sulfate 
(LDS) loading buffer and 100 mM DTT were added. After electro-
phoresis, gels were visualized using an Odyssey CLx infrared imaging 
system. Western blotting was carried out with PVDF (Immobilon-FL 
Membrane; Merck Millipore) and an anti–lamin B1 (1:1,000; Protein-
tech) antibody. Blots were visualized with an anti–rabbit CF800 sec-
ondary antibody (1:20,000; Biotium) and an Odyssey CLx imager.
Statistics. Values are expressed as mean ± SEM or mean ± SD as 
stated. Data were analyzed using GraphPad Prism 6.0. Parametric 
statistical analyses were applied when data showed normal distribu-
tion; otherwise nonparametric tests were used. The statistical analysis 
was conducted at 95% confidence level, with a P value less than 0.05 
being considered statistically significant (***P ≤ 0.001, **P ≤ 0.01, 
*P ≤ 0.05). PMT recordings were normalized to a rolling average 
before plotting as a function of time; period analysis was carried out 
using RAP software 50, and Cosinor analysis was carried out using 
Cosinor.exe version 2.3 (http://www.circadian.org/softwar.html). All 
animals were randomized to treatment and control groups, and inves-
tigators were blinded to genotype and treatment.
Study approval. All animal studies were ethically reviewed and 
carried out in accordance with standards defined by the Animals (Sci-
entific Procedures) Act, United Kingdom, 1986 or European Directive 
86/609/EEC and the GlaxoSmithKline Policy on the Care, Welfare and 
Treatment of Animals.
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